Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Zosano Pharma Corp | exhibit321.htm |
| EX-31.2 - EXHIBIT 31.2 - Zosano Pharma Corp | exhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 - Zosano Pharma Corp | exhibit311.htm |
| EX-23.1 - EXHIBIT 23.1 - Zosano Pharma Corp | exhibit231marcum.htm |
| EX-10.32 - EXHIBIT 10.32 - Zosano Pharma Corp | cfoemploymentagreement.htm |
| EX-10.23 - EXHIBIT 10.23 - Zosano Pharma Corp | exhibittrinity.htm |
| EX-10.17 - EXHIBIT 10.17 - Zosano Pharma Corp | exhibithhchangeordera01.htm |
| EX-10.13 - EXHIBIT 10.13 - Zosano Pharma Corp | exhibit1013b.htm |
| EX-4.2 - EXHIBIT 4.2 - Zosano Pharma Corp | exhibit42description.htm |
| 10-K - 10-K - Zosano Pharma Corp | a10kfy2019.htm |
Exhibit 23.2
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-213567 and 333-229686) and Form S-8s (File Nos. 333-203039, 333-218502, 333-225527 and 333-233284) of our report (which includes an emphasis of matter paragraph as to the Company’s ability to continue as a going concern) dated March 12, 2020, with respect to our audit of the financial statements of Zosano Pharma Corporation as of December 31, 2019 and for the year-ended December 31, 2019 appearing in the Annual Report on Form 10-K of Zosano Pharma Corporation for the year ended December 31, 2019.
By: | /s/ Deloitte & Touche LLP | |
Deloitte & Touche LLP | ||
San Francisco, CA | ||
March 12, 2020 | ||